Evidence map›Paper›PMID 23016110›Full record

ArticleSports health2012

Recommendations of the national football league physician society task force on the use of toradol(®) ketorolac in the national football league.

Matthew Matava, D Craig Brater, Nancy Gritter, Robert Heyer, Douglas Rollins, Theodore Schlegel, Robert Toto, Anthony Yates

Registry-linked trialAbstract read
In one paragraph

Article in Sports health, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06081101 (Ultrasound Guided Sacroiliac Joint Injections With Ketorolac Versus Corticosteroid), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06081101 early_phase1not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Ultrasound Guided Sacroiliac Joint Injections With Ketorolac Versus Corticosteroid: A Prospective Non-inferiority Study

TypeinterventionalSponsorMcMaster UniversityRan2025 to 2026Enrolled20ConditionsSacro-iliac Joint PainArmsMethylprednisolone Injection, Ketorolac Injection
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. What to Cover When You're Covering: Preparing the Sideline Physician for the Season.Journal of the Pediatric Orthopaedic Society of North America · 2024
    Review
  4. Article
  5. Observational
  6. Letter to the editor.Sports health · 2013
    Article
  7. Letter to the editor response.Sports health · 2013
    Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Matthew MatavaMatthew Matava: Washington University, St. Louis, MO.
D Craig Brater
Nancy Gritter
Robert Heyer
Douglas Rollins
Theodore Schlegel
Robert Toto
Anthony Yates
Carolinas Medical Center · USWashington University in St. Louis · USIndiana University – Purdue University Indianapolis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ketorolac tromethamine (Toradol(®)) is a non-steroidal anti-inflammatory drug that has potent analgesic and anti-inflammatory properties. It can be administered orally, intravenously, intramuscularly, or via a nasal route. Ketorolac injections have been used for several years in the National Football League (NFL), in both the oral and injectable forms, to treat musculoskeletal injuries and to prevent post-game soreness. In an attempt to determine the appropriate use of this medication in NFL players, the NFL Team Physician Society appointed a Task Force to consider the best available evidence as to how ketorolac should be used for pain management in professional football players. These treatment recommendations were established based on the available medical literature taking into consideration the pharmacokinetic properties of ketorolac, its accepted indications and contraindications, and the unique clinical challenges of the NFL. The Task Force recommended that 1) ketorolac should only be administered under the direct supervision and order of a team physician; 2) ketorolac should not be used prophylactically as a means of reducing anticipated pain either during or after participation in NFL games or practices and should be limited to those players diagnosed with an injury or condition and listed on the teams' injury report; 3) ketorolac should be given in the lowest effective therapeutic dose and should not be used in any form for more than 5 days; 4) ketorolac should be given in its oral preparation under typical circumstances; 5) ketorolac should not be taken concurrently with other NSAIDs or by those players with a history of allergic reaction to ketorolac, other NSAIDs or aspirin; and 6) ketorolac should not be used by a player with a history of significant gastrointestinal bleeding, renal compromise, or a past history of complications related to NSAIDs.

Identifiers

PMID23016110
PMCPMC3435943
OpenAlexW1963705911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.